Ciber, Inc. (CBR) was initiated by analysts at Maxim Group with a Buy rating and a price target of $7.00 per share
The company will release its third quarter 2015 financial results before market open on Thursday, October 29, 2015
Ciberis a global IT consulting company with some 6,500 consultants in North America, Europe and Asia/Pacific, and approximately $1 billion in annual business.
Brokerage firm Jefferies initiated coverage on Ignyta, Inc. (RXDX) shares with a Buy rating and a price objective of $18.00
Ignytais a precision oncology biotechnology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients.
Investment analysts at Stifel upgraded shares of Equifax Inc. (EFX) from Hold to Buy with a price target of $120.00
Equifax recently delivered third quarter 2015 revenue of $667.4 million, a 9% increase year over year, and adjusted EPS of $1.14, up 13% versus the same period the prior year
Equifax is a global leader in consumer, commercial and workforce information solutions that provides businesses of all sizes and consumers with insight and information they can trust.
Research firm RBC Capital Markets maintained a Top Pick rating on Raytheon Co. (RTN)'s stock and increased its price target from $132.00 to $133.00. Analysts at Stifel also boosted their price objective on the company's stock from $125.00 to $130.00, while maintaining a Buy rating
Raytheon posted strong revenue growth and cash flow generation in the third quarter 2015.
Raytheon is a technology and innovation leader specializing in defense, civil government and cybersecurity markets throughout the world.
Perrigo Company plc (PRGO)'s stock was reiterated with a Neutral rating by equities researchers at B. Riley & Co. They also raised their price objective on shares of the company from $218.00 to $229.00
Perrigo reported record third quarter 2015 net sales of $1.34 billion and GAAP net income of $113 million, or $0.77 diluted earnings per share for the period
Perrigo Company, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers patients and customers high quality products at affordable prices.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer